JP Morgan Chase
VAXX

JP Morgan Chase’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

JP Morgan Chase’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,902
Closed -$32.2K – 7867
2024
Q1 		$32.2K Buy
44,902
+17,048
+61% +$12.4K ﹤0.01% 6094
2023
Q4 		$23.7K Buy
27,854
+229
+0.8% +$221 ﹤0.01% 6214
2023
Q3 		$37.8K Sell
27,625
-6,451
-19% -$14K ﹤0.01% 5890
2023
Q2 		$85.9K Buy
34,076
+33,964
+30,325% +$71.9K ﹤0.01% 5529
2023
Q1 		$0 Buy
+112
New +$284 ﹤0.01% 7355

Other funds holding VAXX

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

JP Morgan Chase's VAXX Position: Q2 2024 in Review

JP Morgan Chase sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 44,902 shares — an estimated $32.2K sold.

JP Morgan Chase first reported a position in VAXX in Q1 2023 and held it in 5 quarters. The position peaked at $85.9K in Q2 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • JP Morgan Chase reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 44,902 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $32.2K.
  • JP Morgan Chase first reported a position in Vaxxinity, Inc. Class A Common Stock in Q1 2023 and held it in 5 quarters.
  • JP Morgan Chase's Vaxxinity, Inc. Class A Common Stock position peaked at $85.9K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.